Back to Search Start Over

Magnetic Resonance Imaging-Guided Thrombolysis (0.6 mg/kg) Was Beneficial for Unknown Onset Stroke Above a Certain Core Size: THAWS RCT Substudy

Authors :
Kazunori Toyoda
Manabu Inoue
Sohei Yoshimura
Hiroshi Yamagami
Makoto Sasaki
Mayumi Fukuda-Doi
Kazumi Kimura
Koko Asakura
Kaori Miwa
Takao Kanzawa
Masafumi Ihara
Rei Kondo
Masayuki Shiozawa
Masafumi Ohtaki
Kenji Kamiyama
Ryo Itabashi
Toru Iwama
Junya Aoki
Kazuo Minematsu
Haruko Yamamoto
Masatoshi Koga
Ban Mihara
Wataru Mouri
Eisuke Furui
Yukako Yazawa
Yukiko Enomoto
Yusuke Egashira
Yusuke Yakushiji
Taizen Nakase
Ryosuke Doijiri
Yasuhiro Ito
Junichiro Suzuki
Yoshinari Nagakane
Eijiro Tanaka
Yasushi Okada
Seiji Gotoh
Shuichi Igarashi
Hideyuki Ohnishi
Hiroyuki Ohnishi
Akira Tsujino
Yohei Tateishi
Shunya Takizawa
Kazunari Homma
Yoshiaki Shiokawa
Rieko Suzuki
Nobuyuki Sakai
Kenichi Todo
Nobuyuki Ohara
Yasuhiro Hasegawa
Naoshi Sasaki
Shuji Arakawa
Masato Osaki
Tsuyoshi Inoue
Yasushi Takagi
Yasuhisa Kanematsu
Shinichi Yoshimura
Yoshikazu Uesaka
Takao Urabe
Masao Watanabe
Toshihiro Ueda
Shoichiro Sato
Toshimitsu Hamasaki
Megimi Sakakibara
Takanari Kitazono
Toshiho Ohtsuki
Wataru Shimizu
Takashi Sozu
Teruyuki Hirano
Kohsuke Kudo
Naomi Morita
Ken Kuwahara
Akira Oita
Kenta Seki
Toshihiro Ide
Takashi Okada
Hajime Ikenouchi
Hiromi Ohara
Mihoko Uotani
Kayo Murata
Shoko Kamiyoshi
Haruka Kanai
Azusa Tokunaga
Ai Ito
Source :
Stroke. 52(1)
Publication Year :
2020

Abstract

Background and Purpose: We determined to identify patients with unknown onset stroke who could have favorable 90-day outcomes after low-dose thrombolysis from the THAWS (Thrombolysis for Acute Wake-Up and Unclear-Onset Strokes With Alteplase at 0.6 mg/kg) database. Methods: This was a subanalysis of an investigator-initiated, multicenter, randomized, open-label, blinded–end point trial. Patients with stroke with a time last-known-well >4.5 hours who showed a mismatch between diffusion-weighted imaging (DWI) and fluid-attenuated inversion recovery were randomly assigned (1:1) to receive alteplase at 0.6 mg/kg intravenously or standard medical treatment. The patients were dichotomized by ischemic core size or National Institutes of Health Stroke Scale score, and the effects of assigned treatments were compared in each group. The efficacy outcome was favorable outcome at 90 days, defined as a modified Rankin Scale score of 0 to 1. Results: The median DWI-Alberta Stroke Program Early CT Score (ASPECTS) was 9, and the median ischemic core volume was 2.5 mL. Both favorable outcome (47.1% versus 48.3%) and any intracranial hemorrhage (26% versus 14%) at 22 to 36 hours were comparable between the 68 thrombolyzed patients and the 58 control patients. There was a significant treatment-by-cohort interaction for favorable outcome between dichotomized patients by ASPECTS on DWI ( P =0.026) and core volume ( P =0.035). Favorable outcome was more common in the alteplase group than in the control group in patients with DWI-ASPECTS 5 to 8 (RR, 4.75 [95% CI, 1.33–30.2]), although not in patients with DWI-ASPECTS 9 to 10. Favorable outcome tended to be more common in the alteplase group than in the control group in patients with core volume >6.4 mL (RR, 6.15 [95% CI, 0.87–43.64]), although not in patients with volume ≤6.4 mL. The frequency of any intracranial hemorrhage did not differ significantly between the 2 treatment groups in any dichotomized patients. Conclusions: Patients developing unknown onset stroke with DWI-ASPECTS 5 to 8 showed favorable outcomes more commonly after low-dose thrombolysis than after standard treatment. Registration: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT02002325. URL: https://www.umin.ac.jp/ctr ; Unique Identifier: UMIN000011630.

Details

ISSN :
15244628
Volume :
52
Issue :
1
Database :
OpenAIRE
Journal :
Stroke
Accession number :
edsair.doi.dedup.....2385f63ead00310687850df310ebb69d